The ICT4LIFE Project - Design and Development of a New Information Technology Platform for Patients with Alzheimer’s Disease

2017 ◽  
Author(s):  
Viktor Voros
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Information Technology ◽  
Project Design ◽  
Design And Development ◽  
Technology Platform ◽  
New Information

scholarly journals Integrating Biomarker Outcomes into Clinical Trials for Alzheimer’s Disease in Down Syndrome

2020 ◽  
pp. 1-4 ◽  
Author(s):  
M.S. Rafii ◽  
S. Zaman ◽  
B.L. Handen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Down Syndrome ◽  
Natural History ◽  
New Information ◽  
History Of ◽  
Clinically Meaningful Outcomes

The NIH-funded Alzheimer’s Biomarker Consortium Down Syndrome (ABC-DS) and the European Horizon 21 Consortium are collecting critical new information on the natural history of Alzheimer’s Disease (AD) biomarkers in adults with Down syndrome (DS), a population genetically predisposed to developing AD. These studies are also providing key insights into which biomarkers best represent clinically meaningful outcomes that are most feasible in clinical trials. This paper considers how these data can be integrated in clinical trials for individuals with DS. The Alzheimer’s Clinical Trial Consortium - Down syndrome (ACTC-DS) is a platform that brings expert researchers from both networks together to conduct clinical trials for AD in DS across international sites while building on their expertise and experience.

Recent Studies on Design and Development of Drugs Against Alzheimer’s Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents

2020 ◽  
Vol 20 (13) ◽  
pp. 1195-1213 ◽  
Author(s):  
Satya P. Gupta ◽  
Vaishali M. Patil
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Tau Protein ◽  
Protein Misfolding ◽  
Inhibition Mechanism ◽  
Design And Development ◽  
Causative Agents ◽  
Misfolding Disease ◽  
Structural Aspects

Background: Alzheimer’s disease (AD) is one of the neurodegenerative diseases and has been hypothesized to be a protein misfolding disease. In the generation of AD, β-secretase, γ-secretase, and tau protein play an important role. A literature search reflects ever increasing interest in the design and development of anti-AD drugs targeting β-secretase, γ-secretase, and tau protein. Objective: The objective is to explore the structural aspects and role of β-secretase, γ-secretase, and tau protein in AD and the efforts made to exploit them for the design of effective anti-AD drugs. Methods: The manuscript covers the recent studies on design and development of anti-AD drugs exploiting amyloid and cholinergic hypotheses. Results: Based on amyloid and cholinergic hypotheses, effective anti-AD drugs have been searched out in which non-peptidic BACE1 inhibitors have been most prominent. Conclusion: Further exploitation of the structural aspects and the inhibition mechanism for β-secretase, γ-secretase, and tau protein and the use of cholinergic hypothesis may lead still more potent anti-AD drugs.

Memory for new information as a cognitive marker of liability to Alzheimer's disease in a high risk group: a research note

2003 ◽  
Vol 18 (2) ◽  
pp. 155-160 ◽  
Author(s):  
Frances Rice ◽  
Richard Abraham ◽  
Varuni Rudrasingham ◽  
Michael J. Owen ◽  
Julie Williams
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
High Risk ◽  
Risk Group ◽  
High Risk Group ◽  
Research Note ◽  
New Information ◽  
Group A

scholarly journals LRRK2p.G2019S Mutation Is Not Common among Alzheimer’s Disease Patients in Brazil

2009 ◽  
Vol 27 (1) ◽  
pp. 13-16 ◽  
Author(s):  
Cíntia Barros Santos-Rebouças ◽  
Cláudia Bueno Abdalla ◽  
Paloma Águia Martins ◽  
Fábio José Rodrigues Baldi ◽  
Jussara Mendonça Santos ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Late Onset ◽  
Linkage Peak ◽  
Lrrk2 Mutation ◽  
Cellular Processes ◽  
New Information ◽  
Lrrk2 Gene ◽  
Different Populations

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have emerged as a potential common cause for both sporadic and familial Parkinson’s Disease (PD) in different populations. The pleomorphic features exhibited by LRRK2 mutation carriers and the central role of Lrrk2 protein in the proper functioning of central nervous system suggest that mutations in this protein might be involved in multiple cellular processes leading to other neurodegenerative disorders than PD. The location of LRRK2 gene on chromosome 12, close to a linkage peak for familial late-onset Alzheimer’s Disease (AD), highlights that LRRK2 mutations might be involved in AD pathogenesis. We screened the most common LRRK2 mutation (p.G2019S) in a series of 180 consecutive patients clinically diagnosed with Alzheimer Disease (AD). We identified the p.G2019S in one AD patient with no PD signs, indicating that this mutation is not a common etiological factor for AD in our population (0.5%), corroborating recent data found in Norwegian, North American, Chinese and Italian populations. Nevertheless, these observations together with new information about the Lrrk2 critical multifunctionality do not rule out the possible influence of other variants within LRRK2 in AD, so that other screenings focusing in the whole extension of the LRRK2 using larger sized confirmed AD sample are urgently needed.

scholarly journals TRC-PAD: ACCELERATING RECRUITMENT OF AD CLINICAL TRIALS THROUGH INNOVATIVE INFORMATION TECHNOLOGY

2020 ◽  
pp. 1-8
Author(s):  
G.A. Jimenez-Maggiora ◽  
R. Raman ◽  
S. Bruschi ◽  
O. Langford ◽  
M. Donohue ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Information Technology ◽  
Clinical Trials ◽  
Information Management ◽  
Modular Design ◽  
Early Stage ◽  
Cost Effective ◽  
Management Platform ◽  
Study Participants

BACKGROUND: The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Informatics Platform (TRC-PAD IP) was developed to facilitate the efficient selection, recruitment, and assessment of study participants in support of the TRC-PAD program. Objectives: Describe the innovative architecture, workflows, and components of the TRC-PAD IP. Design: The TRC-PAD IP was conceived as a secure, scalable, multi-tiered information management platform designed to facilitate high-throughput, cost-effective selection, recruitment, and assessment of TRC-PAD study participants and to develop a learning algorithm to select amyloid-bearing participants to participate in trials of early-stage Alzheimer’s disease. Setting: TRC-PAD participants were evaluated using both web-based and in-person assessments to predict their risk of amyloid biomarker abnormalities and eligibility for preclinical and prodromal clinical trials. Participant data were integrated across multiple stages to inform the prediction of amyloid biomarker elevation. Participants: TRC-PAD participants were age 50 and above, with an interest in participating in Alzheimer’s research. Measurements: TRC-PAD participants’ cognitive performance and subjective memory concerns were remotely assessed on a longitudinal basis to predict participant risk of biomarker abnormalities. Those participants determined to be at the highest risk were invited to an in-clinic screening visit for a full battery of clinical and cognitive assessments and amyloid biomarker confirmation using positron emission tomography (PET) or lumbar puncture (LP). Results: The TRC-PAD IP supported growth in recruitment, screening, and enrollment of TRC-PAD participants by leveraging a secure, scalable, cost-effective cloud-based information technology architecture. Conclusions: The TRC-PAD program and its underlying information management infrastructure, TRC-PAD IP, have demonstrated feasibility concerning the program aims. The flexible and modular design of the TRC-PAD IP will accommodate the introduction of emerging diagnostic technologies.

scholarly journals Alzheimer’s disease care and management: Role of information technology

2007 ◽  
Vol 2 (3) ◽  
pp. 91-95 ◽  
Author(s):  
Hanuman Thota ◽  
Allam Appa Rao ◽  
Kiran kumar Reddi ◽  
Sivaprasad Akula ◽  
Suresh Babu Changalasetty ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Information Technology ◽  
Role Of Information
Sign in / Sign up

Export Citation Format

Share Document